Statistical Significance Versus Clinical Importance in Population PK

Two Different Questions About a Covariate Effect

A population PK analysis may estimate a covariate effect precisely enough to distinguish it from zero, yet the estimated difference may be too small to matter for exposure or treatment decisions. Conversely, an estimate may be large enough to raise clinical concern while remaining too uncertain to meet a conventional significance criterion. These are not contradictory results: statistical significance and clinical importance answer different questions.

Statistical significance concerns how compatible the observed estimate is with a specified null hypothesis, such as no covariate effect, under a statistical model. Clinical importance concerns whether the size of the effect would matter in a defined clinical context. A p-value alone does not answer the second question. The effect estimate, its uncertainty, and an appropriate clinical benchmark must be considered together.

The benchmark should be defined on an interpretable effect scale and justified by clinical or pharmacological context. There is no universal percentage that makes every PK covariate effect clinically important. For the examples below, assume that the relevant contrast and a benchmark of a 10% change have already been specified for the analysis. The task here is to distinguish evidence against no effect from evidence about whether the estimated magnitude is consequential.

Testing a Zero-Effect Hypothesis

Suppose a model estimates a covariate effect as a parameter ratio \(R\): the typical PK parameter for one level of the covariate, or one specified covariate condition, divided by that for the reference condition. The ratio \(R=1\) represents no difference. A ratio of 1.08 represents an 8% increase, while a ratio of 0.92 represents an 8% decrease. These ratios are dimensionless; the underlying PK parameter, such as clearance, has its own units.

A convenient scale for inference is \(\theta=\log(R)\). No effect corresponds to \(\theta=0\), and ratios above or below one correspond to positive or negative values of \(\theta\). If the estimated log-ratio \(\hat{\theta}\) is approximately normally distributed with estimated standard error \(SE(\hat{\theta})\), a two-sided Wald test uses:

Under \(H_0:\theta=0\), this statistic is approximately standard normal, \(Z\sim N(0,1)\). The two-sided p-value is \(2P(Z\geq |z|)\). At a prespecified significance level \(\alpha=0.05\), the test is statistically significant when the p-value is at most 0.05. The test addresses whether the data provide evidence that the effect differs from zero; it does not test whether the effect exceeds a clinical threshold.

A corresponding approximate 95% confidence interval on the log scale is \(\hat{\theta}\pm1.96SE(\hat{\theta})\). Exponentiating both endpoints gives an interval for \(R\). This interval is useful for examining plausible effect magnitudes as well as whether the interval includes 1. It does not assign a 95% probability to the fixed true ratio; rather, the 95% confidence procedure would cover the true ratio in 95% of repeated samples under its assumptions.

This approximation relies on a reasonably well-behaved estimator and a reliable standard error. It is most defensible when the population PK model is adequately specified, the estimation has converged, the covariate is sufficiently represented in the data, and the standard error captures the relevant uncertainty. Repeated observations within a participant are not independent observations; their dependence must be handled by the population model. If data are sparse, the model is unstable, or the estimate is near a problematic boundary, a simple Wald approximation may be unreliable.

Worked Examples: Significance and Importance Can Diverge

What to Check Before Drawing a Conclusion

A significance result is only as dependable as its model, estimator, and standard error. In population PK work, assess whether the model converged satisfactorily, whether the covariate has adequate representation across its range or categories, and whether estimates are sensitive to influential observations or plausible modeling choices. Sparse individual information, strong correlation among covariates, and misspecification of the structural or covariate model can undermine the apparent precision of an estimate. A small p-value cannot repair those problems.

Also consider how the covariate was selected. If many covariates or functional forms were tested and only a promising result is reported, a nominal p-value from the selected model may overstate the strength of evidence. Selection and validation approaches address aspects of that problem, but they do not change the distinction between statistical and clinical importance.

A clinical benchmark should be defensible, expressed on the same effect scale as the estimate, and set without simply choosing a convenient value after seeing the result. A benchmark based on a percentage change in clearance is not automatically equivalent to the same percentage change in exposure or to a treatment decision. Those links require clinical and pharmacological reasoning beyond the significance test.

The reverse mistake is to treat \(p<0.05\) as proof that a covariate matters clinically. With a sufficiently precise estimate, even a very small difference can be statistically significant. A useful report therefore gives the effect estimate on an interpretable scale, its uncertainty, the statistical test result when relevant, and the clinical benchmark used to interpret magnitude. The conclusion should distinguish what the analysis detects from what the estimated size may mean.